spoke to simon
the 'close out' costs have inflated the costs for Q4 which will not be replicated in q1-q2. By closing out in q4 they have more data to be able to go to the FDA with re 2 x 2 and BT etc i believe. The issue is clearly that even assuming they are sure on their forecasts and they get their R+D, they dont have a lot of cash by end June
Paul has publicly stated a regional deal by H1... sadly here i think almost everything rests on that.
They will soon i hope confirm 2 x 2. Let's hope they try for any get breakthrough. Let's hope they get an MPS deal. But ultimately they need a china deal to get the shares to 65c to exercise the options to finish the trials without further funding.
MPS - see the reason for the delay. I wish they said this earlier but the reason for the delay is nothing untoward i believe.
- Forums
- ASX - By Stock
- PAR
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-26
-
- There are more pages in this discussion • 211 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
30.5¢ |
Change
0.005(1.67%) |
Mkt cap ! $104.9M |
Open | High | Low | Value | Volume |
30.5¢ | 30.5¢ | 29.5¢ | $51.07K | 170.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 43091 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 105372 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 33007 | 0.300 |
7 | 118987 | 0.295 |
6 | 86653 | 0.290 |
6 | 78665 | 0.285 |
5 | 113816 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.305 | 105120 | 8 |
0.310 | 20519 | 4 |
0.320 | 36284 | 2 |
0.325 | 51547 | 5 |
0.330 | 58393 | 5 |
Last trade - 11.25am 17/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |